The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients

Author： Komiya  

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.1, Iss.2, 2013-01, pp. : 257-262

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy

By Gerritsen Winald   Sharma Padmanee  

Journal of Clinical Immunology, Vol. 32, Iss. 1, 2012-02 ,pp. : 25-35

Springer Publishing Company

Access to resources Recommend Favorite

Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs

By Slovin Susan F  

Immunotherapy, Vol. 5, Iss. 12, 2013-12 ,pp. : 1347-1355

Future Medicine

Access to resources Recommend Favorite

Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials

By              

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 1182-1188

Spandidos Publications

Access to resources Recommend Favorite

Prostate cancer vaccines: an old yet novel target, the androgen receptor

By Arlen Philip M  

Expert Review of Vaccines, Vol. 12, Iss. 3, 2013-03 ,pp. : 249-251

Informa Healthcare

Access to resources Recommend Favorite

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer

By Mazzucchelli Roberta  

Cellular Oncology, Vol. 34, Iss. 3, 2011-06 ,pp. : 235-243

Springer Publishing Company

Access to resources Recommend Favorite